Navigation Links
ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Date:6/17/2008

d supply of clinical material until transfer of manufacturing.

TB-403 (Anti-PIGF) has completed an initial Phase I clinical trial and recently received approval to enter a Phase Ib dose escalation trial. This Phase Ib trial will be conducted in patients with advanced cancer and is due to commence shortly in Denmark.

TB-403 has the potential to be a major advance in the treatment of cancer. It is a humanized monoclonal antibody that blocks the formation of the new blood vessels that are needed by solid tumours to support their growth. TB-403 has the potential to minimize both the growth and spread of cancer cells.

Professor Désiré Collen, CEO and Chairman of ThromboGenics, said: "TB-403 has generated a great deal of interest from the pharmaceutical community. Therefore, we are delighted that we have signed this major licensing agreement with Roche, given their expertise and success in bringing novel anti-cancer agents to the market. This deal represents a significant milestone in ThromboGenics' development as a company. It also reflects TB-403's potential as a promising treatment for cancer, and is a testament to the hard work and high quality science on which ThromboGenics' business is based. The funding from this deal also gives us the financial resources to continue to build our strong pipeline. We look forward to working with Roche, and to the successful development of this unique anti-cancer agent."

Svein Mathisen, CEO of BioInvent, commented on the deal: "We believe that TB-403 has great potential for the treatment of cancer, with its unique mode of action targeting PlGF, and are delighted that Roche has recognised this potential. This agreement demonstrates our ability to identify innovative projects and to realize the clinical potential of a therapeutic antibody. We look forward to seeing the product progress further through clinical development and towards market."

Dan Zabrowski, Global Head of Pharma Partnering, Roche adde
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015 YourEncore, an ... life sciences, consumer products and food sciences industries ... the Alliance for Clinical Research Excellence and Safety ... for conducting clinical research, have partnered to speed ... , YourEncore brings to ACRES experts with ...
(Date:4/20/2015)... MENLO PARK, Calif. , April ... (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical ... therapies in new orphan drug indications, today announced ... Meeting of the American Association for Cancer Research ... its lead product candidate VAL-083 (dianhydrogalactitol) ...
(Date:4/20/2015)... , April 20, 2015 ... for healing bone injuries. The orthobiologics market is a ... for its stakeholders. The global orthobiologics market report defines ... of revenue. The global orthobiologics market was valued at ... $7,900.2 million by 2019, at a CAGR of 6.7% ...
(Date:4/20/2015)... 20, 2015 PointCross Life Sciences today announced ... an integrated Big Data and globally accessible environment for ... the context of clinical trials and nonclinical studies. This ... drug candidates, stratified patient selection and ex post ... Highlighting the timing of this partnership, ...
Breaking Biology Technology:YourEncore and ACRES Partner to Drive Innovation in Clinical Research 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3PointCross Life Sciences and InterpretOmics partner for Clinical and Genomic Biomarker Management for Drug Development 2
... TUALATIN, Ore. , Jan. 26 Waytronx, ... to the acquisition, development, and commercialization of new, innovative ... with British-based Ingenion Design Ltd. ("Ingenion") to develop and ... (GasPT2). , The GasPT2, designed by GL Industrial Services ...
... SHANGHAI , Jan. 26 /PRNewswire-Asia/ ... Company in China , announced,that a French delegation led ... January 22, 2010 . M.Raffarin, currently President,of Foundation Prospective ... Mr. Erwan Davoux of the foundation, and Dr. ...
... , , STOCKHOLM ... - part of,the Karolinska Development portfolio - announced today ... to continue its clinical,development program. Based on cardio-protective effects, ... new therapy for treating acute,coronary syndrome (ACS) and reperfusion ...
Cached Biology Technology:Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 2Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 3Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 4Former French Prime Minister Jean-Pierre Raffarin Visits Sundia 2Eribis Pharmaceuticals Receives Investment for Clinical Development of Novel Cardiovascular Therapy 2
(Date:4/1/2015)... 1, 2015   Medisafe ™, the leading global ... iOS and Android smartphones and ... into the platform to allow patients to track and ... first time, patients will be able to visualize in ... important biometrics, such as glucose levels and blood pressure. ...
(Date:3/31/2015)... , March 31, 2015   Guidepoint , ... launch of the Post-Surgical Pain Management TRACKER, part of ... tracking usage trends in the medical device and therapeutics ... to data including treatment volumes, market share, and adoption ... pain associated with joint surgery. The Post-Surgical ...
(Date:3/26/2015)... , March 26, 2015 The ... social, recreation and athletic club, today announced it has ... allow freedom of movement for members and staff, while ... a comprehensive process, we selected FST,s IMID Access system ... convenience for our members and staff, in addition to ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... vulnerable to their environment during embryonic development than females, ... University of Glasgow in the UK. Until now, the ... conditions during the embryonic stage in birds have received ... in Springers journal, Behavioral Ecology and Sociobiology. In ...
... of PocketCop Software, WALL, N.J., May 6 ... leader in finger-based biometric,identification and wireless public safety ... latest mobile data solution for BlackBerry(R),smartphones at the ... be held May 7-9 at the Gaylord Opryland ...
... brand now includes hi-tech gun and storage chest, ... BMRX), today announced that it has added two new ... which are,immediately available at retailers and online specialty sites., ... products as we grow our,smartTOUCH product line of consumer ...
Cached Biology News:Seagulls: Are males the weaker sex? 2BIO-key(R) Showcasing Public Safety Solutions for BlackBerry Smartphones at 2008 LEIM Conference 2BIO-key(R) Showcasing Public Safety Solutions for BlackBerry Smartphones at 2008 LEIM Conference 3bioMETRX, Inc. Introduces New Products 2
... serine/threonine phosphatase isolated from human red blood ... of 60kDa (A) and 36kDa (C) subunits. ... a-subunit of phosphorylase kinase. With its 3638kDa ... and may play a regulatory role in ...
... ATP Monitoring Kit measures adenosine ... sensitivity and a dynamic range. ... the assay measures ATP in ... over a concentration range of ...
... refrigerated cold traps offers a choice of ... solvents or high volatility solvents. Ideal to ... evaporators. Also used for maintaining vapor-free gas ... in electron microscopes. Can be used as ...
96 Well Plate Sterile, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
Biology Products: